High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast

Bone Marrow Transplantation

Volumn 24, Issue 9, 1999, Pages 981-987

  Schwartzberg, L S ^a   Weaver, C H ^a   Lewkow, L ^a   McAneny, B ^a   Zhen, B ^a   Birch, R ^a   West, W H ^a   Tauer, K W ^a   Buckner, C D ^a,b  

^a Clin Res Div Response Oncol I   (United States)

^b Response Oncology Inc   (United States)

Author keywords

High dose therapy; Inflammatory breast cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0032714427     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701965     Document Type: Article

References (46)

1. Lopez M, Porter K. Inflammatory breast cancer. Surg Clin North Am 1996; 76: 411-428.
2. Booser J, Hortobagyi G. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19: 278-285.
3. Fastenberg N, Martin R, Buzdar A et al. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol 1985; 8: 134-141.
4. Levine P, Steinhorn S, Ries L, Aron J. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985; 74: 291-297.
5. Israël L, Breau J, Morere J. Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. Cancer 1986; 57: 24-28.
6. Burton G, Cox E, Leight G Jr et al. Inflammatory breast carcinoma. Effective multimodal approach. Arch Surg 1987; 122: 1329-1332.
7. Brun B, Otmezguine Y, Feuilhade F et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 1988; 61: 1096-1103.
8. Perez C, Fields J, Fracasso P et al. Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma. Cancer 1994; 74: 466-476.
9. Rouëssé J, Friedman S, Sarrazin D et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765-1771.
10. Maloisel F, Dufour P, Bergerat J et al. Results of initial doxorubicin, 5-fluorouracil and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65: 851-855.
11. Buzdar A, Singletary S, Booser D et al. Combined modality treatment of stage III and inflammatory breast cancer. Surg Clin North Am 1995; 76: 715-735.
12. Chevallier B, Bastit P, Graic Y et al. The Centre H Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993; 67: 594-601.
13. Fields J, Perez C, Kuske R et al. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys 1989; 17: 249-255.
14. Fields J, Kuske R, Perez C et al. Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis. Cancer 1989; 63: 1225-1232.
15. Thorns W Jr, McNeese M, Fletcher G et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1989; 17: 739-745.
16. Elias E, Vachon D, Didolkar M, Aisner J. Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast. Am J Surg 1991; 162: 231-235.
17. Gardin G, Rosso R, Campora E et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 1995; 31A: 1428-1433.
18. Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
19. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
20. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, 1995, pp 59-85.
21. Gianni A, Siena S, Bregni M et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-years results. J Clin Oncol 1997; 15: 2312-2321.
22. de Graaf H, Willemse P, de Vries E et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1997; 30A: 150-153.
23. Antman K, Rowlings P, Vaughan W et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
24. Schwartzberg LS, Birch R, West WH et al. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers. Am J Clin Oncol 1998; 21: 523-531.
25. Schwartzberg L, Birch R, Tauer K et al. Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with 5-9 involved axillary lymph nodes. Am J Clin Oncol 1999; 22: 136-142.
26. Schwartzberg L, Weaver C, Birch R et al. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. J Hematother 1998; 7: 141-150.
27. Ayash L, Elias A, Wheeler C et al. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother 1993; 2: 507-511.
28. Antman K, Ayash L, Elias A et al. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr 1994; 16: 91-94.
29. Antman KH. Dose-intensive therapy in breast cancer. In: Armitage JO, Antman KH (eds). High-dose Cancer Therapy (Pharmacology, Hematopoietins, Stem cells). Williams & Wilkins: Baltimore, 1992, pp 701-717.
30. Ayash L, Elias A, Ibrahim J et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000-1007.
31. Cagnoni P, Nieto Y, Shpall E et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16: 1661-1668.
32. American Cancer Society 1989 Cancer Statistics. CA-A Cancer J Clin 1989; 39.
33. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.
34. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
35. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
36. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896-903.
37. Weaver C, Zhen B, Schwartzberg L et al. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide and G-CSF with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 1998; 21: 141-150.
38. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997 3: 83-90.
39. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
40. Weaver CH, Schwartzberg LS, Hainsworth J et al. Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671-678.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
42. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc 1972; 135: 185-198.
43. Somlo G, Doroshow J, Forman S et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997; 15: 2882-2893.
44. Adkins D, Brown R, Beck E et al. Outcomes of high-dose chemotherapy and autologous stem cell transplant in stage IIIB inflammatory breast cancer. Proc Am Soc Clin Oncol 1997; 16: 104a.
45. Cunningham J, Weiss S, Ahamed S et al. The efficacy of neo-adjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 1998; 16: 80-86.
46. Feldman L, Hortobagyi G, Buzdar A et al. Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-2581.